CSF-1R inhibitors, such as PLX3397, deplete M2 macrophages and enhance CD8+ T cell activity, improving objective response rates (ORR) in MSI-H CRC (20%–30%) (Shimizu et al., 2024). The gene discussed is CD8A; the disease is colorectal carcinoma.